Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 19/20 | 0.70 |
| ▸ | ADRB1 | P08588 | 18/20 | 0.70 |
| ▸ | ADRB3 | P13945 | 17/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.70 |
| ▸ | MEN1 | O00255 | 2/20 | 0.70 |
| ▸ | TP53 | P04637 | 2/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.70 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.70 |
| ▸ | HTR1A | P08908 | 1/20 | 0.70 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.70 |
| ▸ | DRD2 | P14416 | 1/20 | 0.70 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.70 |
| ▸ | DRD4 | P21917 | 1/20 | 0.70 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.70 |
| ▸ | FPR3 | P25089 | 1/20 | 0.70 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.70 |
| ▸ | HTR1D | P28221 | 1/20 | 0.70 |
| ▸ | HTR1B | P28222 | 1/20 | 0.70 |
| ▸ | HTR2A | P28223 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29751132 | 1.00 | ADRB2 (0.70) | ADRB2ADRB1ADRB3KDM4EMEN1 | |
| SCHEMBL9864677 | 0.98 | ADRB2 (0.67) | ADRB2ADRB1ADRB3KDM4EMEN1 | |
| SCHEMBL10697205 | 0.96 | ADRB2 (0.64) | ADRB2ADRB1ADRB3KDM4EMEN1 | |
| SCHEMBL5008664 | 0.91 | ADRB2 (0.60) | ADRB2ADRB1ADRB3KDM4EMEN1 | |
| SCHEMBL10701369 | 0.87 | ADRB2 (0.53) | ADRB2ADRB1ADRB3KDM4EMEN1 | |
| Carboxynaphthol SCHEMBL462270 | 0.86 | ADRB2 (0.78) | ADRB2ADRB1ADRB3KDM4EMEN1 | |
| SCHEMBL10338191 | 0.86 | ADRB2 (0.52) | ADRB2ADRB1ADRB3KDM4EMEN1 | |
| SCHEMBL10514014 | 0.85 | ADRB2 (0.52) | ADRB2ADRB1ADRB3KDM4EMEN1 | |
| SCHEMBL10513403 | 0.84 | ADRB2 (0.50) | ADRB2ADRB1ADRB3KDM4EMEN1 | |
| SCHEMBL8438453 | 0.84 | ADRB2 (0.74) | ADRB2ADRB1ADRB3KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4992474-A | Adrenergic stimulants | GLAXO GROUP LTD. (GB) | 1991-02-12 | — | — | US | claimed |
| CN-114685291-A | Preparation method and application of salmeterol | 天津药业研究院股份有限公司 | 2022-07-01 | — | — | CN | disclosed |
| EP-1937626-B1 | Process and intermediates for the preparation of Salmeterol | GENERICS UK LTD (GB) | 2016-02-17 | — | — | EP | disclosed |
| US-20140349969-A1 | COMPOUNDS AND METHODS FOR TREATING PAIN | AKRON MOLECULES AG (AT) | 2014-11-27 | — | — | US | disclosed |
| US-8648214-B2 | Processes suitable for the preparation of salmeterol | GENERICS [UK] LIMITED (GB) | 2014-02-11 | — | — | US | disclosed |
| US-8648214-B2 | Processes suitable for the preparation of salmeterol | GENERICS [UK] LIMITED (GB) | 2014-02-11 | — | — | US | disclosed |
| EP-2674161-A1 | FMO3 inhibitors for treating pain | Akron Molecules GmbH (AT) | 2013-12-18 | — | — | EP | disclosed |
| US-20130252924-A1 | Compounds and Methods for Treating Pain | AKRON MOLECULES GMBH (AT) | 2013-09-26 | — | — | US | disclosed |
| EP-2641893-A1 | PROCESS FOR THE PREPARATION OF SALMETEROL AND ITS SALTS | Generics [UK] Limited (GB) | 2013-09-25 | — | — | EP | disclosed |
| EP-2641893-A1 | PROCESS FOR THE PREPARATION OF SALMETEROL AND ITS SALTS | Generics [UK] Limited (GB) | 2013-09-25 | — | — | EP | disclosed |
| EP-1937626-A1 | NOVEL PROCESS | Merck Generics (UK) Limited (GB) | 2008-07-02 | — | — | EP | disclosed |
| US-20080020019-A1 | METHOD OF DECREASING FAT DEPOSITS AND BODY WEIGHT IN MAMMALS AND BIRDS | ABERG A K G | 2008-01-24 | — | — | US | disclosed |
| WO-2007045857-A1 | NOVEL PROCESS | GENERICS (UK) LIMITED (GB) | 2007-04-26 | — | — | WO | disclosed |
| WO-2007045857-A1 | NOVEL PROCESS | GENERICS (UK) LIMITED (GB) | 2007-04-26 | — | — | WO | disclosed |
| US-20060293293-A1 | Salmeterol and ciclesonide combination | ALTANA PHARMA AG (DE) | 2006-12-28 | — | — | US | disclosed |
| US-20050129620-A1 | Metering valve and pharmaceutical metered dose inhaler and methods thereof | GLAXO GROUP LIMITED (GB) | 2005-06-16 | — | — | US | disclosed |
| US-20050113456-A1 | Method of decreasing fat deposits and body weight in mammals and birds | ALTERAGON PTY LTD. (AU) | 2005-05-26 | — | — | US | disclosed |
| EP-0536250-B1 | AEROSOL DRUG FORMULATIONS | GLAXO WELLCOME INC (US) | 2000-09-06 | — | — | EP | disclosed |
| US-5376359-A | Mixing solid particular drug with fluoro-polymer and fluorocarbon propellant, cooling to adsorb | GLAXO, INC. (US) | 1994-12-27 | — | — | US | disclosed |
| US-5126123-A | Soluble surfactant stabilizer | GLAXO, INC. (US) | 1992-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140349969-A1 | COMPOUNDS AND METHODS FOR TREATING PAIN | TRPV1, ACHE, OPRL1 | ADRB2 237/4885ADRB1 497/4885ADRB3 219/4885 |
| US-20060293293-A1 | Salmeterol and ciclesonide combination | NR5A1, HSD3B1, NR3C2 | ADRB2 191/4885ADRB1 92/4885ADRB3 57/4885 |
| US-20130252924-A1 | Compounds and Methods for Treating Pain | TRPV1, ACHE, OPRL1 | ADRB2 237/4885ADRB1 497/4885ADRB3 219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.